# AMIX — Autonomix Medical Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** AMIX  
**Sources:** 250  
**Published:** 2026-07-30  
**Canonical:** https://app.k3vl4r.com/research/deep-research-amix-autonomix-medical-inc-catalysts-narrative-risks-1259

---

As of 2026‑07‑30, Autonomix Medical Inc. (ticker AMIX) has emerged as a key player in the precision nerve‑targeted medical device sector, with a robust pipeline that spans pain management, hypertension, and other nerve‑related conditions [[1]](https://www.marketwatch.com/investing/stock/amix). The company’s recent catalysts—centered on its warrant inducement agreement, clinical conference presentations, and upcoming shareholder events—have positioned AMIX for a potential 12‑month price target between $42.00 and $58.82, translating into an upside potential of roughly 1,400 % from the last trade [[1]](https://www.marketwatch.com/investing/stock/amix)[[3]](https://stockanalysis.com/stocks/amix/forecast/)[[7]](https://stockstotrade.com/news/autonomix-medical-inc-amix-news-2026_07_24/).

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-amix-autonomix-medical-inc-catalysts-narrative-risks-1259 (free to sign up)._